Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 6, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
DURHAM, N.C. --(BUSINESS WIRE)--Dec. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
- Appointed Michael Amoroso as President and Chief Executive Officer and to Board of Directors; Sam Wadsworth , Ph.D., and Shari Lisa Piré, J.D., Appointed to Board of Directors - Hosted In Vivo Gene…
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 9, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
New Directors Add Decades of Cell and Gene Therapy Development and Strategic Business Growth Experience DURHAM, N.C. --(BUSINESS WIRE)--Nov. 8, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a…
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology
- Enhanced Lymphodepletion Improved Overall Response Rate and Complete Response Rate Compared to Standard Lymphodepletion in Heavily Pretreated NHL and B-ALL Subjects with a Median of ~6 Prior Lines…
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27, 2021
DURHAM, N.C. --(BUSINESS WIRE)--Oct. 21, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS ® genome editing platform to develop allogeneic CAR…
Precision BioSciences Statement on Safety of its Allogeneic CAR T Cells
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T and in vivo gene editing therapies, issued the…
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS® genome editing platform to develop allogeneic CAR T…
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 27, 2021-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company using its ARCUS genome editing platform to develop allogeneic CAR T…
